Peter Goadsby, PhD DSc FRACP FRCP FMedSci FRS

Professor of Neurology and Honorary Consultant Neurologist
University of Leeds UK, King Abdullah University of Science and Technology, Saudi Arabia,NIHR King’s Clinical Research Facility, & SLaM Biomedical Research Centre, and The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK, United Kingdom

Poster(s):

• (T 3) TRPM8 Channel Blockade with Elismetrep in a Phase 2B study: A Novel Approach for Treating Migraine

• (T 5) Weight Loss With Atogepant Versus Topiramate: Post hoc Analysis of the Head-to-Head TEMPLE Trial

• (E 65) Unmet patient needs in migraine prevention: an international survey of real-world impact, preventive medication use, and drivers of discontinuation

• (T 02) Long-Term Safety, Tolerability, and Efficacy of Atogepant for the Preventive Treatment of Migraine: Final Results from a Phase 3, Open-Label, 156-Week, Long-Term Safety Extension Study

• (T 18) Treatment outcomes with rimegepant versus other standard of care acute migraine medications in the observational CONFIDENCE study

• (T 40) Ubrogepant Efficacy Based on Historical Cutaneous Allodynia and Triptan Response: Results from the PRODROME Trial

• (T 41) Efficacy of Ubrogepant 100 mg Based on Prior Triptan Experience: Results From the ACHIEVE I Study